CHA Biotech said on the 9th that its U.S. subsidiary Matica Biotechnology signed a contract with Surgem Bioscience for contract development and manufacturing (CDMO) of adeno-associated virus (AAV) vectors. Surgem Bioscience is a local gene therapy corporations.
Adeno-associated viruses cause little immune response in the body and are used as gene delivery vehicles. Matica Biotechnology develops processes and analytical methods needed to develop adeno-associated virus vectors. It manufactures the vectors and supplies them to Surgem Bioscience.
The two companies agreed not to disclose the contract amount. Matica Biotechnology was established by CHA Biotech to enter the U.S. cell and gene therapy (CGT) market. Cell and gene therapies are next-generation medicines that fundamentally cure diseases by modifying a patient's cells or genes.